NRx Pharmaceuticals to Present at Upcoming Investor Conferences
News related to:NRx Pharmaceuticals, Inc · 2 min read
WILMINGTON, Del., Sept. 08, 2026 /CourierPR/ -- NRx Pharmaceuticals, a clinical-stage biopharmaceutical company, will participate in three upcoming investor conferences in September 2026, aiming to present updates on its product pipeline and strategic plans.
The company’s management team, led by Founder, Chairman, and CEO Jonathan Javitt, M.D., M.P.H., will present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference on September 9, 2026, from 9:35 to 9:55 a.m. Eastern Time. NRx Pharmaceuticals will provide an overview of its therapeutic development efforts, focusing on its NMDA platform for treating central nervous system disorders, including suicidal depression, chronic pain, and PTSD. The company is currently developing NRX-100, a preservative-free intravenous ketamine, and NRX-101, a combination of oral D-cycloserine and lurasidone.
On September 11, 2026, Javitt will also participate in a fireside chat at the 2026 Cantor Global Healthcare Conference. This event will offer investors a deeper insight into the company's progress and future strategies. NRx Pharmaceuticals has already achieved regulatory milestones, including Fast Track Designation for NRX-100 in the treatment of suicidal ideation in depression, including bipolar depression, and Breakthrough Therapy Designation for NRX-101 in the treatment of suicidal bipolar depression.
The company’s CEO will also address a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026, from 2:30 p.m. Eastern Time. This presentation is expected to cover the company’s recent developments and future outlook.
NRx Pharmaceuticals has filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100 with an application for the Commissioner's National Priority Voucher Program for the treatment of suicidal ideation in patients with depression, including bipolar depression. These regulatory efforts underscore the company's commitment to advancing its drug candidates for unmet medical needs.
In addition to the presentations, NRx Pharmaceuticals will provide live webcasts and replays of each session on its website, making the information accessible to a broader audience. The company’s website, NRxPharma.com, will host the webcasts, ensuring that investors and the public can follow the presentations remotely.
NRx Pharmaceuticals continues to advance its clinical-stage biopharmaceuticals, with a focus on addressing significant health challenges such as suicidal depression, chronic pain, and PTSD. The company’s presentations at the upcoming investor conferences will provide a platform for detailed discussions on its therapeutic strategies and the potential impact of its research on patient care.
By engaging with investors and healthcare professionals, NRx Pharmaceuticals aims to build a stronger foundation for the future of its product development and market presence.